Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands |
Aug. 06, 2018 |
Mar. 13, 2018 |
Jan. 25, 2018 |
Jan. 08, 2018 |
May 31, 2018 |
Mar. 09, 2018 |
|---|---|---|---|---|---|---|
| Statement Line Items [Line Items] | ||||||
| Aggregate ordinary shares | 3,333,336 | 400,000 | ||||
| Warrants to purchase shares | 2,500,002 | |||||
| Aggregate purchase price | $ 5,000 | |||||
| Warrants issued | 982,344 | |||||
| Warrants term | The warrants may be exercised after 6 months from the date of issuance for a period of five and a half years. | |||||
| Subsequent Event [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Aggregate ordinary shares | 3,333,336 | |||||
| Warrants to purchase shares | 2,500,002 | |||||
| Aggregate purchase price | $ 5,000 | |||||
| Total upfront and milestone payment | $ 2,200 | |||||
| Warrants issued | 982,344 | |||||
| Warrants term | The warrants may be exercised after 6 months from the date of issuance for a period of five and a half years and have an exercise price of USD 2.00 per ADS (subject to certain adjustments) | |||||
| Subsequent Event [Member] | Placement agent warrants [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Warrants to purchase shares | 166,667 | |||||
| Subsequent Event [Member] | ADS [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Aggregate ordinary shares | 6,666,672 | |||||
| Warrants to purchase shares | 5,000,004 | |||||
| Warrant exercise price | $ 2.00 | |||||
| Subsequent Event [Member] | ADS [Member] | Placement agent warrants [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Warrants to purchase shares | 333,334 | |||||
| Warrant exercise price | $ 2.00 | |||||
| Subsequent Event [Member] | Gebro Holding [member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Sale of milestone description | (i) €300 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 and €1,600 following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 and up to €4,025 upon meeting certain net sales. | |||||
| Subsequent Event [Member] | Gebro Holding [member] | Euro [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Total upfront and milestone payment | $ 1,500 | |||||
| Subsequent Event [Member] | CMS Medical [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Warrants term | Under the License, Collaboration and Distribution Agreement, the Company is entitled to USD 2,000 upon execution of the agreement plus milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing Piclidenoson and Namodenoson. | |||||
| Received upfront payment | $ 2,000 | |||||
| Subsequent Event [Member] | March 2014 Financing [Member] | ||||||
| Statement Line Items [Line Items] | ||||||
| Warrants issued | 98,234 |